Novel Paired Normal Prostate and Prostate Cancer Model Cell Systems Derived from African American Patients.
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
19
05
2022
revised:
27
07
2022
accepted:
30
11
2022
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Prostate cancer is the most frequently diagnosed solid malignancy in men. African American (AA) men are at greater risk for developing prostate cancer, and experience higher mortality rates, as compared with Caucasian American men. However, mechanistic studies to understand this health disparity have been limited by the lack of relevant Cells derived from prostatectomies of AA patients conferred a bimodal cellular phenotype, recapitulating clinical prostate cellular complexity in this model cell system. Comparisons of viability responses of tumor derived to normal epithelial cells offer the potential for screening therapeutic drugs. Therefore, these paired prostate epithelial cell cultures provide an
Identifiants
pubmed: 36970725
doi: 10.1158/2767-9764.CRC-22-0203
pii: CRC-22-0203
pmc: PMC10035501
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Pagination
1617-1625Subventions
Organisme : NCI NIH HHS
ID : HHSN261201800016C
Pays : United States
Informations de copyright
© 2022 The Authors; Published by the American Association for Cancer Research.
Déclaration de conflit d'intérêts
M. Jung reports other from Shuttle Pharmaceuticals, Inc outside the submitted work. S. Grindrod reports grants from Shuttle Pharmaceuticals Inc during the conduct of the study; grants from Shuttle Pharmaceuticals Inc outside the submitted work. A. Dritschilo reports grants from NIH SBIR during the conduct of the study; other from Shuttle Pharmaceuticals, Inc. outside the submitted work. No disclosures were reported by the other authors.
Références
Cancer Causes Control. 2006 Aug;17(6):803-11
pubmed: 16783608
J Natl Cancer Inst. 1986 Jan;76(1):45-8
pubmed: 3455741
Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20035-40
pubmed: 23169653
Prostate. 2011 Jun 15;71(9):985-97
pubmed: 21541975
Mol Cancer. 2013 Aug 30;12(1):99
pubmed: 24001151
J Natl Cancer Inst. 2001 Feb 7;93(3):219-25
pubmed: 11158191
Am J Pathol. 2012 Feb;180(2):599-607
pubmed: 22189618
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Am J Pathol. 2013 Dec;183(6):1862-1870
pubmed: 24096078
J Natl Cancer Inst. 2009 Jul 15;101(14):984-92
pubmed: 19584328
Int J Oncol. 2009 Oct;35(4):751-60
pubmed: 19724911
Breast Cancer Res Treat. 2015 Sep;153(2):311-21
pubmed: 26283301
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Cancer Res. 2008 Feb 1;68(3):927-36
pubmed: 18245496
Cell Death Dis. 2018 Oct 24;9(11):1089
pubmed: 30356039
Br J Cancer. 2001 Aug 3;85(3):422-7
pubmed: 11487275
Clin Cancer Res. 2016 Dec 15;22(24):6153-6163
pubmed: 27384421
Sci Rep. 2015 Dec 07;5:17792
pubmed: 26639154
Nat Protoc. 2017 Feb;12(2):439-451
pubmed: 28125105
Nat Rev Dis Primers. 2021 Feb 4;7(1):9
pubmed: 33542230
J Pathol. 2004 Jun;203(2):661-71
pubmed: 15141381
Oncotarget. 2015 Jun 20;6(17):15594-609
pubmed: 25909225
Nat Rev Cancer. 2010 Jun;10(6):441-8
pubmed: 20448633
Genes Dev. 2018 Sep 1;32(17-18):1105-1140
pubmed: 30181359
JAMA Oncol. 2017 Dec 1;3(12):1663-1672
pubmed: 28494073
Genes Dev. 2010 Sep 15;24(18):1967-2000
pubmed: 20844012
Oncotarget. 2017 Apr 4;8(14):22741-22758
pubmed: 28009986
Cancer Res. 1997 Feb 1;57(3):524-31
pubmed: 9012485
J Clin Invest. 2010 Jul;120(7):2619-26
pubmed: 20516646
Nat Commun. 2016 Feb 29;7:10798
pubmed: 26924072
J Pathol. 2001 Dec;195(5):563-70
pubmed: 11745692
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4482-7
pubmed: 27044116